Colossal Biosciences in talks to raise at up to $30B — tripling its valuation
What's the deal? Colossal Biosciences, the de-extinction startup working to bring back species such as the woolly mammoth and the dodo, is in talks to raise new capital at a valuation of $20 billion to $30 billion, according to Axios. The round's lead investor and target size haven't surfaced yet.
Why it matters. The talks would roughly double-to-triple the company's valuation in about 16 months. Colossal last raised a $200M Series C in January 2025 at a $10.2B valuation, led by TWG GlobalDealroom has a profile for this one. Try Dealroom →, and has since pulled in follow-on capital including a reported $60M from the UAE. Founded in 2021 and run out of a Dallas HQ, the five-year-old company is backed by investors ranging from In-Q-Tel to Peter Jackson.
From moonshot to revenue. CEO Ben LammDealroom has a profile for this one. Try Dealroom → has said the company began generating revenue over the past year across three streams: licensing its conservation and genetic-engineering technology (to customers including the U.S. government and the UAE), spinning out companies built on its core science, and — eventually — selling biodiversity credits if it succeeds in reintroducing extinct animals to the wild. It has already spun out three startups: Form BioDealroom has a profile for this one. Try Dealroom → (computational biology), Breaking (plastic degradation), and Astromech (AI-driven biological modelling, valued at $2B in March 2026).
The signal. A $20–$30B mark would be a striking bet on an ambitious, still-unproven scientific mission, and reflects investor appetite for high-risk, high-upside deep tech amid a broader boom in longevity and biotech. Colossal added the bluebuck antelope as its sixth target species in April 2026, and its underlying tech — including an artificial-womb platform Lamm expects to be ready in 2027 — is what backers are really underwriting.
Read more: TechCrunch · The Tech Buzz
